337 results on '"BRAMWELL, VIVIEN"'
Search Results
2. Supplementary Figure S3 from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
3. Supplementary Figures 1-2 from A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
4. Supplementary Tables S1-S5 from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
5. Soft Tissue Sarcoma Surveillance Counterpoint: Canada
6. Contribution of Osteopontin to the Development of Bone Metastasis
7. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
8. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
9. Adjuvant chemotherapy of soft tissue sarcomas
10. Combination of Chronic Indomethacin and Intermittent IL-2 Therapy in the Treatment of Disseminated Cancer
11. Adjuvant Chemotherapy for Soft Tissue Sarcomas
12. Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials
13. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
14. Soft Tissue Sarcoma Surveillance Counterpoint: Canada
15. Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases
16. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas
17. Sarcomas of Soft Tissue
18. Abstract P2-11-03: Predictive significance of an optimized immunohistochemical panel for basal-like breast cancer on the CCTG MA.12 phase III randomized clinical trial
19. Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
20. Controversies in Surgical Oncology: Routine Anthracycline-based Adjuvant Chemotherapy for Stage III Extremity Soft Tissue Sarcoma
21. Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases
22. High-dose continuous venous infusion of interleukin-2: Influence of dose and infusion rate on tumoricidal function and lymphocyte subsets
23. Anthracyclines in Early Breast Cancer
24. HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
25. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort
26. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
27. Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5
28. Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
29. Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group
30. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
31. Caution with breast-conserving surgery
32. Anastrozole Versus Tamoxifen as First-Line Therapy For Advanced Breast Cancer: Methodologic Issues
33. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma
34. Adjuvant Chemotherapy for Adult Soft Tissue Sarcoma: Is There a Standard of Care?
35. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
36. Adjuvant chemotherapy of soft tissue sarcomas
37. Osteosarcoma and other tumors of bone
38. Osteosarcoma and other tumors of bone
39. A Pilot Study of Adriamycin, Dacarbazine and Ifosfamide in Advanced Adult Soft Tissue Sarcomas
40. European Experience of Adjuvant Chemotherapy for Soft Tissue Sarcoma: Interim Report of a Randomized Trial of Cyvadic Versus Control
41. Adjuvant chemotherapy for soft tissue sarcomas
42. Adjuvant chemotherapy for soft tissue sarcomas
43. When to Consider Adjuvant/Neoadjuvant Therapy for Adult Soft-Tissue Sarcoma
44. Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas
45. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study
46. The disposition of cyclophosphamide in a group of myeloma patients
47. Pazopanib and the treatment palette for soft-tissue sarcoma
48. Abstract P3-09-02: Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: Analysis of adjuvant studies conducted by NCIC Clinical Trials Group (NCIC CTG)
49. Abstract P4-11-11: CADER prognostic gene signature for disease free survival in hormone receptor positive breast cancer: NCIC CTG MA.12 phase III placebo-controlled tamoxifen trial
50. Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.